Lars Frelin

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.

Journal: Molecular therapy. Advances

Published: July 05, 2025

Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells.

Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells.

Journal: Gastroenterology

Published: July 10, 2023

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease.

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 08, 2023

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

Journal: Gut

Published: February 18, 2022

A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.

A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.

Journal: EMBO molecular medicine

Published: February 04, 2022

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

Journal: Clinical & translational immunology

Published: March 30, 2021

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.

Journal: Journal of virology

Published: July 15, 2020

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: June 15, 2020

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Journal: Human vaccines & immunotherapeutics

Published: December 07, 2019

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.

Journal: The Journal of infectious diseases

Published: October 05, 2019

Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers.

Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers.

Journal: Journal of pediatric gastroenterology and nutrition

Published: September 28, 2017

Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C.

Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C.

Journal: Journal of pediatric gastroenterology and nutrition

Published: August 19, 2017

Showing 1-12 of 33

Last Updated: 09/26/2026